After 15 years in Biotech Tom Froggatt set up Singular Talent to help Biotech companies engage, attract and secure the talent they need and to make the hiring experience better from both sides of the table. He revealed how the values that are the bedrock of the company and .... much more:
Why I started Singular Talent
When I started in recruitment in 2006, the biggest problem we faced was finding and contacting the right people. LinkedIn didn’t exist, and Google was nowhere near the platform it’s now become, so we spent all of our time (and money) on solving this problem – building databases…
Fremont, CA, US and Cambridge, UK – 04 January 2022 – Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.
The field of proteomic analysis is in the spotlight. Its advance not only enhances the understanding of fundamental biology, but also sheds light on the status of human health and disease. A deeper…
MAINZ, Germany and CAMBRIDGE, UK, January 10, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Crescendo Biologics Ltd (“Crescendo”), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. The initial term of the discovery collaboration is three years.Crescendo will contribute its unique, proprietary, transgenic platform to deliver fully human heavy-chain antibody domains (…
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Research has shown that ACE2 mediates COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. AMSBIO’s new Spike neutralizing monoclonal antibodies (clone G10xA5 and G10xA1) recognize the SARS-CoV-2 Spike RBD (B.1.1.…
• UK CFOs focused on business expansion in 2022
• Record* number of CFOs say increasing capital investment is a strong priority for their business in the year ahead
• Overwhelming majority of CFOs expect greater investment in digital technology and workforce skills over the next three years
• Despite rising inflation and the emergence of the Omicron variant, CFO risk appetite has nudged higher
• CFOs expect productivity to grow faster in the next three years, than in the years before the pandemic
Finance leaders are focused on growth, with a record 37% rating an increase in capital…
Cambridge, UK and Durham, NC, USA, 05 January 2022: PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, today announced a collaboration to study oncology targets currently considered undruggable.
Under the terms of the agreement, the POLARISqb Tachyon™ quantum computing platform will be used to scan billions of molecules from a large chemical space, to find novel molecular drugs, based on the information obtained from PhoreMost’s…
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will be responsible for all future…
Innovate UK, the National Institute of Health Research (NIHR; i4i programme and AI in Health and Care Award) and the Small Business Research Initiative (SBRI) Healthcare have joined forces to offer specialist support to companies within their portfolios, from across the UK, via their Investment Readiness Programme. The programme will support selected companies to gain additional skills and expertise to get them prepared to find and attract investment.
Delivered by Bionow, the not-for-profit membership organisation, the Investment Readiness Programme has been specifically designed for UK…
Leading pharmaceutical and biotech product development consultancy, Boyds, has hired regulatory expert in the pharma, biotech and medical devices sectors, Eamonn McGowran as Associate Director.
Based at Boyds’ Irish operation at Talent Garden Dublin, Eamonn’s appointment marks the beginning of the next phase of growth and expansion in Dublin and Europe for Boyds, which will harness his leading and specialist regulatory experience in medical devices to boost and enhance its comprehensive regulatory advice and services portfolio.
Boyds’ Dublin office represents the consultancy’s gateway to…